P1204: AXICABTAGENE CILOLEUCEL VEIN-TO-VEIN TIME IN TRIAL OR REAL-WORLD SETTINGS VS OTHER CAR T-CELL THERAPIES FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

• Frederick Locke,
• Michael T. Hemmer,
• Steve Kanters,
• Michael J. Zoratti,
• Zhen-Huan Hu,
• Harry Miao,
• Shilpa Shahani,
• Clare Spooner,
• Christine Fu,
• Anik Patel,
• Hairong Xu,
• Marcelo Pasquini

Affiliations

Frederick Locke

1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States

Michael T. Hemmer

2 Kite, a Gilead Company, Santa Monica, United States

Steve Kanters

3 RainCity Analytics, Vancouver, Canada

Michael J. Zoratti

3 RainCity Analytics, Vancouver, Canada

Zhen-Huan Hu

2 Kite, a Gilead Company, Santa Monica, United States

Harry Miao

2 Kite, a Gilead Company, Santa Monica, United States

Shilpa Shahani

2 Kite, a Gilead Company, Santa Monica, United States

Clare Spooner

2 Kite, a Gilead Company, Santa Monica, United States

Christine Fu

2 Kite, a Gilead Company, Santa Monica, United States

Anik Patel

2 Kite, a Gilead Company, Santa Monica, United States

Hairong Xu

2 Kite, a Gilead Company, Santa Monica, United States

Marcelo Pasquini

4 Center for International Blood and Marrow Transplant Research, Milwaukee, United States